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After peripheral nerve injury, nociceptive afferents acquire an abnormal excitability to adrenergic 
agents that is linked with behavioural signs of pain [3; 11; 25; 26; 31; 34; 44]. Likewise, in chronic 
pain states such as post-herpetic neuralgia, cutaneous neuromas, amputation stump pain and 
complex regional pain syndrome (CRPS), intradermal administration of α1-adrenoceptor (α1-AR)  
agonists into affected sites may evoke aberrant pain that can persist for 30-60 minutes [2; 7-9; 27; 
29; 51].  
Within the central nervous system, quantitative radioligand binding studies in animal models have 
demonstrated an increased neural expression of α1-ARs on surviving neurons after spinal transection 
or chemical lesion of adrenergic neurons [16; 37; 43]. Similarly, within the peripheral nervous 
system, messenger RNA for the α1B-AR increased in rat dorsal root ganglia following peripheral nerve 
section or ligation of spinal nerves supplying those ganglia [31; 57]. Importantly, the proportion of 
dorsal root ganglion neurons that responded to norepinephrine increased markedly after nerve 
injury induced by loose or tight ligation of the sciatic nerve [39]. Conversely, the α1-AR antagonist 
prazosin inhibited nociceptive fibre discharge in neuropathic pain models when given systemically 
[20; 23; 34]. Together, these findings suggest that an increased neural expression of α1-ARs after 
peripheral nerve injury increases the excitability of nociceptive afferents. 
We recently used immunohistochemistry to identify α1-ARs on nociceptive fibres in normal rat skin 
[10], but whether α1-AR expression changes on these nerve fibres after peripheral nerve injury is 
unknown. Hence, the aim of this study was to determine whether neural expression of α1-ARs 
increased in the skin after partial sciatic nerve ligation (PSL) in rats, and in CRPS following a 
peripheral nerve injury in humans (causalgia or CRPS type II).  PSL is a well-characterized model of 
CRPS type II associated with allodynia to light touch and hyperalgesia to noxious mechanical and 




guanethidine, an agent that displaces norepinephrine from sympathetic adrenergic neurons [30; 47]. 
Involvement of the sympathetic nervous system in CRPS is controversial [6]; nevertheless, 
adrenergic agonists aggravate pain in a subpopulation of CRPS patients [2; 9; 29; 51], and many 
patients with CRPS type II report long-term benefits after sympathectomy of the affected limb [5; 
18]. Thus, we hypothesized that α1-AR expression would increase on nerve fibres in the skin and 
sciatic nerve trunk after PSL in rats, and on nerve fibres in the skin of humans with CRPS type II.  
Methods 
Animals and surgery  
Experiments were approved by the Murdoch University and Royal North Shore Hospital Animal Care 
and Ethics Committees. Tissues were obtained from 6 – 8 week old Wistar rats obtained from Animal 
Resources Centre (Canning Vale, Australia), following the guidelines of the ‘NH&MRC Code of 
Practice for the Care and Use of Animals in Research in Australia’. Animals were housed in groups of 
three in individually ventilated cages under a 12-12 hour light-dark cycle, with environmental 
enrichment and free access to water and standard rat chow. The PSL model of nerve injury was 
performed using the method outlined by Seltzer et al. [45]. Briefly, the left sciatic nerve was exposed 
at mid-thigh level and a 4–0 silk suture inserted into the nerve to tightly ligate the dorsal 1/3 - 1/2 of 
the nerve trunk approximately 3 mm proximal to the trifurcation of the sciatic nerve [22]. The 
muscle (4–0) and then the skin (3–0) were closed with silk sutures. Sham-operated animals 
underwent the same surgery as the PSL-operated animals except that sutures were not inserted into 
the nerve and the nerve was not ligated. Six animals were examined in each experimental group. 
Mechanical allodynia was assessed prior to surgery (baseline) and again prior to perfusion either 4 or 
28 days post-surgery in all animals using a series of Von Frey hairs to test the paw withdrawal 
threshold (range 0.2 g to 15 g) using the up-down paradigm outlined by Jayamanne et al. [22]. 
Animals were tested in batches of four mixed sham/PSL animals and the experimenter was blinded 




Tissue processing and immunohistochemistry 
Rats were heavily anesthetized with an intraperitoneal injection of sodium pentobarbitone 
(100mg/kg, Thiobarb, Jurox Pty. Ltd, NSW, Australia). Each rat was transcardially perfused with 
heparinized saline (0.2% v/v heparin, Mayne Pharma Pty Ltd, Melbourne, Australia and 0.9% w/v 
NaCl2, pH 7.4) followed by 4% v/v formalin in 0.9% w/v NaCl2, pH 7.3). The feet were then removed 
and postfixed in the 4% formalin solution for 4 hrs at room temperature. Plantar and hairy skin was 
collected from each hind paw, and then washed in 0.1M Phosphate Buffer (PB, pH 7.4) for 30 min, 
dehydrated in 50% v/v ethanol for 30 min and washed twice in PB for 15 min each. Tissues were 
cyroprotected by incubation for 48 hours in 30% w/v sucrose dissolved in tris phosphate buffered 
saline (TPBS, 0.1M PB, 0.9% w/v NaCl2, 1% w/v tris base, pH 7.4) containing 0.1% w/v sodium azide 
(NaN3) and then mounted in TissueTek® OCT compound (Sakura Finetek, Zoeterwoude, The 
Netherlands) and stored at -80°C until use. 10 µm thick cryosections were cut using a cryostat (Leica 
CM 1850 UV, Nussloch, Germany) and collected onto silane coated slides (Hurst Scientific) and 
stored at -20°C until use.   
Samples of the lesioned sciatic nerve were collected from four PSL animals four days after surgery 
and four sham operated animals at the same time point. Tissues were processed as described above.  
For immunohistochemistry, sections were initially washed in 0.1M PBS (3x10 min) and incubated 
with 0.2% triton X-100 in PBS for 7.5 min at room temperature. Sections were washed with PBS (3x5 
min) and blocked for 2 hrs in 10% donkey serum (Sigma) in PBS at room temperature. Sections were 
then treated with the following combinations of primary antibodies: α1-AR/calcitonin gene related 
peptide (CGRP)/pan neuronal marker (TUJ1) to examine α1-AR expression on peptidergic afferent 
nerve fibres; α1-AR/ isolectin B4 (IB4)/TUJ1 to examine α1-AR expression on non-peptidergic afferent 
nerve fibres; α1-AR/ neurofilament 200 (NF200)/TUJ1 to examine α1-AR expression on myelinated 
fibres; α1-AR/ smooth muscle actin to examine α1-AR expression on blood vessel walls; and myelin 
basic protein (MBP)/ NF200/α1-AR to determine whether α1-ARs were expressed on NF200
+




co-localised with the myelin sheath surrounding these axons (details and dilutions are shown in 
Table 1).  Antibodies were co-incubated for 48 hrs at 4
o
C, diluted in blocking solution. Sections were 
then washed with PBS (3x15 min) and incubated with the appropriate species specific secondary 
antibodies (Table 1) diluted in 5% donkey serum (Sigma) in PBS for 4 hrs at room temperature. 
Sections were washed with PBS (3x15 min) and coverslipped with Prolong Gold anti-fade mounting 
media (Invitrogen). The pattern of staining produced by the α1-AR antibody on blood vessels, nerves 
and keratinocytes resembles the staining pattern produced by BODIPY FL-prazosin, a fluorescent α1-
AR antagonist [10]. In addition, staining is eliminated following pre-adsorption of the anti-sera with 
an α1-AR-specific peptide [10], and the peptide sequence recognized by the α1-AR antibody is not 
found in any other G-protein-coupled receptor or non-receptor protein (National Center for 
Biotechnology Information, National Institutes of Health, BLAST program, 
http://blast.ncbi.nlm.nih.gov/Blast.cgi). A representative example of α1-AR expression on the 
smooth muscle cells of large and small blood vessels is shown in supplementary Figure e1. Two 
consecutive sections per sample were stained and all immunohistochemistry for each staining 
combination was performed at the same time to ensure staining consistency.  No staining was 
observed on negative control sections that had all primary antibodies omitted. 
Human tissue processing and immunohistochemistry 
Each participant provided written informed consent for the procedures, which were approved by the 
Human Research Ethics Committee at Murdoch University. Skin biopsies were collected from two 
women and three men aged between 23 and 56 years who met the clinical criteria for CRPS type II 
[32] (Table 2). The syndrome had begun 6 months to 10 years previously after accidental laceration 
of the ulnar nerve (two cases), surgery involving the sural or median nerve (two cases) or a crush 
injury of the sciatic nerve (one case). In each case, the injury was associated with a region of 
diminished sensation; however, pain and other sensory, autonomic and motor symptoms had 
spread beyond the distribution of the injured nerve. Pain decreased after sympathetic blockade in 




conditions using a 3 mm diameter skin biopsy punch under local anaesthesia. Two biopsies were 
collected per patient; one from a region of hyperalgesia and another from the mirror image site on 
the contralateral limb. For comparison, skin samples were also collected from the dorsolateral 
aspect of one hand in four women and six men aged between 24 and 68 years (mean age 46 ± 15 
years) without chronic pain.  
The biopsies were fixed in Zamboni’s solution (5% formalin and 1% picric acid in 0.9% saline) for 4 
hours at 4°C, washed in PBS, incubated in 50% ethanol for 30 min followed by a further two rinses in 
PBS prior to paraffin embedding and sectioning into 10 µm sections that were collected onto silane 
coated slides (Hurst Scientific).  
Sections were double-labelled for the α1-AR and pan neuronal marker Protein Gene Product-9.5 
(PGP9.5) using immunohistochemistry. As antibodies for each of these labels were raised in rabbit, 
the immunohistochemistry protocol was combined with tyramide signal amplification, which allows 
differentiation between two primary antibodies raised in the same species. Sections were 
deparaffinised through xylene and a descending series of ethanol washes to 0.1M PBS. Antigen 
retrieval was performed by incubation with 1mg/mL porcine trypsin (Sigma-Aldrich) for 20 min at 
37°C. Sections were incubated with 3% H2O2 in PBS for 10 min to quench endogenous peroxidase 
activity, and then treated with 0.2% Triton X-100 in PBS for 5 min prior to incubation with blocking 
solution containing 10% normal donkey serum in PBS for 2 hrs. Next, sections were incubated with 
anti-PGP9.5 diluted 1:400,000 in blocking solution overnight at room temperature (rabbit anti-
PGP9.5; AbD Serotec, USA, Product code 7863-0504), followed by biotin conjugated donkey anti-
rabbit IgG for 1 hr (1:000; Jackson ImmunoResearch), streptavidin-horse radish peroxidase (1:150) 
for 30 min and biotin-conjugated tyramide (1:100 in amplification solution; Tyramide Signal 
Amplification Kit, NEL700; Perkin-Elmer Life Sciences) for 3 min. Sections were then incubated with 
DyLight 549-conjugated streptavidin (1:1000; Jackson ImmunoResearch) for 1 hr. Sequential double 




48hrs at 4°C followed by anti-rabbit DyLight-488 conjugated secondary antibody (1:600; Jackson 
ImmunoResearch) diluted in PBS for 4 hrs at room temperature. Sections were coverslipped with 
Prolong Gold.  
Imaging and quantification of immunohistochemistry 
Images of immunostained sections were collected using a Leica TCS SP2 multiphoton confocal 
microscope by an investigator who was blinded to side and group (PSL/sham and patient/control). 
Each label was collected sequentially at the appropriate excitation and emission spectra. For sciatic 
nerve sections, single images were acquired under 400x magnification, stacking a series of optical 
sections (Z-series) acquired at 1 µm intervals throughout the depth of the tissue. Skin sections were 
examined under 200X magnification with each z-series image collected every 2 µm. Two images, one 
of the papillary dermis containing the epidermis and the dermal nerve fibres, and one of the 
reticular dermis containing the large dermal nerve bundles, were collected for each skin section. 
Quantification was subsequently performed using the maximum projection image of the resulting 
stack. Care was taken to ensure that there was no bleed-through between channels using the 
imaging settings chosen, and all imaging settings were consistent for all sections in each staining run.  
Both in rat and human skin samples, α1-AR staining intensity was quantified in the epidermis, blood 
vessels, nerve fibres in the dermis and nerve fibres in large dermal nerve bundles by a blinded 
investigator. The epidermis was identified by morphology, blood vessels by smooth muscle actin, 
and nerve bundles and fibres in the dermis by pan-neuronal markers (TUJ1 for rat tissue and PGP9.5 
for human tissue). In sections of rat sciatic nerve, α1-AR staining intensity was quantified in axons, 
which were identified by TUJ1 staining. α1-AR staining intensity in each region was quantified in at 
least two sections from each sample and averaged.  
Quantification of α1-AR staining intensity was performed using ImageJ software (Image J, version 
1.47t, National Institute of Health, USA). To determine average pixel intensity on individual nerve 




nerve fibre location, which was then applied to the corresponding α1-AR stained image. This ensured 
that α1-AR expression was only examined in those pixels also positive for TUJ1 or PGP9.5 staining. A 
similar approach was employed to quantify vascular α1-ARs using smooth muscle actin to create a 
mask of blood vessel location. Quantification of α1-AR intensity in the keratinocyte layer of the 
epidermis was performed by manually drawing around the keratinocyte layer and measuring the 
average α1-AR intensity in the defined region.  
α1-AR staining intensity in rat tissue was also quantified in specific neuronal populations; peptidergic 
CGRP
+
 neurons, non-peptidergic IB4
+
 neurons, and myelinated NF200
+
 neurons.  For this 
quantification, a co-localisation analysis using the “Colocalization Finder” plugin for ImageJ was 
performed between each of these specific neuronal markers and TUJ1. This analysis allowed 
identification of all pixels that were immuno-positive for TUJ1 and individual neuronal markers, 
ensuring that all regions included in the resulting mask were these nerve fibres. This mask was then 
applied to the corresponding α1-AR image and α1-AR staining intensity was quantified in these 
neuronal populations.   
Statistical approach  
To combine data for neural markers across multiple immunohistochemistry runs, α1-AR staining 
intensity within each run was expressed in normalized units for each region of interest (the 
keratinocyte layer of the epidermis, dermal blood vessels, nerve fibres in the papillary dermis, and 
nerve bundles in the reticular dermis). Raw scores from the ipsilateral and contralateral sides in 
lesioned and sham animals were combined into a single variable for each run and region, and 
transformed into scores with a mean of 0 and a standard deviation of 1 (i.e., Z-scores). Hence, 
positive scores represented greater than average α1-AR staining intensity, whereas negative scores 
represented less than average α1-AR staining intensity. These normalized scores were averaged 
across multiple immunohistochemistry runs for each animal to obtain a mean score for each region 




skin, these data were also averaged for quantification purposes. Mean scores were then compared 
between the injured and contralateral limb with Wilcoxon’s matched-pairs signed-ranks tests, and 
between experimental and control groups with Mann-Whitney U tests. A similar approach was used 
to investigate differences in α1-AR staining intensity in patients with CRPS Type II versus controls. 
Results are reported as the mean ± standard error, and the criterion of statistical significance was 
p<0.05.  
Results 
Mechanical allodynia after PSL  
Prior to surgery all animals had a paw withdrawal threshold of 15 g. Paw withdrawal threshold in the 
ipsilateral limb was reduced to 0.4 ± 0.2 g at 4 days after PSL surgery and to 0.2 ± 0.1 g at 28 days 
after PSL.  Paw withdrawal threshold was unchanged from baseline levels in all animals that 
underwent sham surgery.  
α1-AR expression in the skin after PSL  
The strongest expression of α1-ARs in the skin was observed in the epidermis. Strong α1-AR 
expression was also observed in hair follicles, blood vessels and nerves, consistent with findings from 
our previous study [10]. This pattern of expression did not change in vascular or epidermal cells 
either 4 or 28 days after PSL. 
PSL resulted in an up-regulation of α1-ARs on papillary dermal nerve fibres identified by the pan-
neuronal marker TUJ1. At 4 days after surgery, α1-AR expression was significantly greater on nerve 
fibres in skin ipsilateral to injury than in animals that underwent sham surgery (p = .015) (Figure 1A). 
The intensity of α1-AR expression in individual sensory nerve populations was then quantified to 
determine whether the up-regulation of α1-AR expression was associated with specific nerve 
population(s). α1-AR expression was significantly greater in non-peptidergic IB4
+
 nerve fibres at 4 
days post-PSL in comparison to animals that underwent sham surgery (p = .032), while α1-AR 
expression was not significantly altered on peptidergic CGRP
+






nerve fibres in the papillary dermis (Figure 1A). α1-AR expression was no longer up-regulated on 
papillary dermal nerve fibres at 28 days after PSL (Figure 1B).  
The intensity of α1-AR expression was also quantified on axons in large nerve bundles in the deeper 
dermis. α1-AR expression was significantly elevated in TUJ1
+
 axons in skin ipsilateral to PSL at 4 days 
post-surgery in comparison to sham animals (p = .015) (Figure 1C). Specific, individual axons within 
nerve bundles were observed to have particularly high expression of α1-AR after PSL (Figure 2), 
which was localized on axons and not in the surrounding connective tissue (Figure 2C). When α1-AR 
expression in individual nerve populations was examined, it was found that α1-AR staining intensity 
was significantly higher in IB4
+
 axons at 4 days after surgery in skin ipsilateral to PSL in comparison to 
animals that underwent sham surgery (p = .017), although this was due largely to an outlier in the 
PSL group (Figure 1C).  As shown in Figure 3, α1-AR staining intensity within NF200
+
 axons was also 
found to be significantly higher in skin ipsilateral than contralateral to PSL at 4 days after surgery (p = 
.028), and higher ipsilateral to PSL than in sham animals (p = .041) (Figure 1C). There was also a 
trend for higher α1-AR expression in CGRP
+
 axons after PSL in comparison to animals that underwent 
sham surgery, but with high variation among animals.  
The up-regulation of α1-AR expression on axons in larger nerve bundles persisted at 28 days after 
PSL. α1-AR expression on TUJ1
+
 axons remained significantly higher in skin ipsilateral to PSL in 
comparison to that from animals that underwent sham surgery (p = .009) (Figure 1D). α1-AR staining 
intensity in skin ipsilateral to PSL remained significantly higher in NF200
+
 axons in comparison to 
those from skin contralateral to PSL (p = .009) and from animals that underwent sham surgery (p = 
.028) (Figure 1D).  
Co-localisation analysis for MBP, NF200 and α1-AR revealed that the vast majority of α1-AR staining 
co-localised with NF200, while there was minimal co-localisation with MBP (Figure 4). As NF200 
stains intracellular neurofilaments in nerve fibres, this suggests that α1-AR was up-regulated on 




α1-AR expression in the sciatic nerve after PSL  
α1-AR was expressed on many axons within the sciatic nerve. Four days after PSL, α1-AR expression 
further increased in IB4+ neurons in comparison to surrounding axons that did not express IB4 
(Figure 5), being 92 ±15% greater in IB4
+
 neurons than in the non- IB4
+
 surrounding axons 4 days 
after PSL surgery compared with 43 ±7% greater in IB4
+
 neurons than in the surrounding non- IB4
+
 
axons 4 days after sham surgery (p = .043). This up-regulation was specific to IB4
+
 axons as there 
were no significant differences in α1-AR expression on axons in the sciatic nerve labelled with CGRP 
or NF200 between the PSL and sham groups.    
α1-AR expression in the skin of patients with CRPS type II  
α1-AR expression on nerve fibres in the dermis was greater in CRPS-affected limbs than in controls (p 
= .001) and, in each case, was greater in the CRPS-affected than unaffected limb of patients with 
CRPS type II (Figure 6A and Figure 7). Similarly, α1-AR expression within the epidermis was greater in 
CRPS-affected limbs than in controls (p = .038) (Figure 6B and Figure 8). However, α1-AR expression 
on blood vessels was similar in patients and controls. In the group as a whole, α1-AR expression on 
dermal nerve fibres and keratinocytes did not differ significantly between the unaffected limb of 
patients with CRPS type II and controls (Figure 6). 
Discussion 
The aim of this study was to determine whether α1-AR expression was up-regulated on nerve fibres 
in the skin in an animal model of CRPS type II and in patients with this condition. Four days after PSL, 
α1-ARs were expressed more strongly on nerve fibres that survived the injury than on nerve fibres in 
animals that underwent sham surgery. This heightened α1-AR expression was observed on non-
peptidergic nociceptive afferents labelled with IB4 in the injured sciatic nerve, in dermal nerve 
bundles, and in the terminal distribution of these nerve fibres. Heightened expression of α1-AR was 
also associated with NF200, a marker of myelinated nerve fibres, in dermal nerve bundles both 4 and 




on surrounding myelin or connective tissue. Furthermore, α1-ARs were expressed more strongly on 
nerve fibres in affected than unaffected skin in patients with CRPS type II and also more strongly 
than that seen in the skin of pain-free controls. Together, these findings provide compelling 
evidence of an up-regulation of α1-ARs on cutaneous nociceptive afferents after peripheral nerve 
injury. As each of the nerve fibre types that expressed α1-ARs after nerve injury also express α1-ARs 
in the uninjured state [10], this up-regulation appeared to involve heightened production of α1-ARs 
rather than expression on nerve fibres that did not previously produce α1-ARs. 
Four days after sciatic nerve injury, α1-ARs were up-regulated on IB4
+
 nerve fibres. These non-
peptidergic unmyelinated nerve fibres form a dense intra-epidermal network that protects the 
organism from potential harm by detecting noxious stimuli at the interface with the external 
environment [49]. This up-regulation was also detected in the sciatic nerve trunk, possibly due to 
increased axonal transport of α1-ARs from production points in the soma or heightened membrane 
expression of α1-ARs along the length of the unmyelinated nerve fibres.  
Up to 28 days after nerve injury, up-regulation of α1-AR expression was also observed on NF200
+
 
nerve fibres in dermal nerve bundles, but this did not extend to the sciatic nerve trunk or the 
papillary dermis. After peripheral nerve injury, NF200 is retained in only a small population of nerve 
fibres in the papillary dermis [38]. Thus, our findings suggest that α1-AR expression was up-regulated 
on NF200
+
 nerve fibres that lost NF200 in the papillary dermis, or that did not retain their superficial 
extensions after nerve injury. NF200 identifies medium- and large-diameter myelinated neurons, 
including A-delta nociceptors that express the tyrosine receptor kinase A (TrkA), a high-affinity 
receptor for nerve growth factor [4]. Many large-diameter nerve fibres that contain neurofilaments 
apparently lose their myelin before terminating in the skin [10; 41] and other peripheral tissues [19] 
(notably, most NF200
+
 nerve fibres within the dermal nerve bundle shown in Figure 4B were 
unmyelinated). It would be interesting to determine whether α1-ARs are expressed preferentially at 




and NF200 was limited to unmyelinated axons in dermal nerve bundles after PSL whereas α1-AR 
expression was increased on unmyelinated IB4
+
 fibres both in dermal nerve bundles and more 
proximally in the sciatic nerve.  
Peripheral nerve injury evokes a complex response involving Wallerian degeneration, modifications 
in the phenotype of surviving neurons, neural regeneration and collateral sprouting. For example, a 
subpopulation of myelinated A-beta fibres that normally signal touch undergoes a phenotypic switch 
that involves increased expression of certain ion channels and membrane receptors [54], and an 
enhanced synthesis of nociceptive neurotransmitters such as substance P and CGRP [35]. This local 
response evokes changes in afferent signalling that result in central sensitisation, cortical 
remodelling and alterations in descending pain modulation processes [55; 58].  Wallerian 
degeneration is associated with an influx of immune cells into damaged nerves which, together with 
damaged axons, resident Schwann cells and target tissues, release inflammatory mediators and 
neurotrophins that reduce the firing threshold and induce transcriptional changes in production of 
neuropeptides, ion channels and membrane receptors in surviving neurons [14; 50; 55]. 
Neurotrophins such as nerve growth factor might trigger the synthesis of α1-AR, as nerve growth 
factor augments the production of α1B-AR in cultured dorsal root ganglion cells and increases their 
responsiveness to norepinephrine via actions on α1-ARs [61]. In turn, heightened α1-AR expression 
could augment neuroinflammatory responses by enhancing the release of inflammatory mediators 
such as substance P and prostaglandin E2 [12; 24; 52]. Following partial peripheral nerve injury, 
sympathetic adrenergic fibres sprout in close proximity to nociceptive fibres, likely due to increased 
levels of nerve growth factor [28; 59]. The apposition of these two fibre types might permit aberrant 
crosstalk due to adrenergic excitation of up-regulated α1-ARs on nociceptive fibres. α1-AR activation 
generally increases neural excitability [17; 36; 40]; hence, stimulation of up-regulated α1-ARs both 





In a radioligand binding study, we previously found that α1-AR density was greater in CRPS-affected 
skin than in the skin of normal controls [13], but the cellular source of this up-regulation could not 
be determined. The present findings suggest that cutaneous nerve fibres are an important source of 
heightened α1-AR expression in the skin of patients with CRPS type II; however, the chief source 
might be keratinocytes, as α1-AR expression was most intense in the epidermis, particularly on the 
affected side in patients with CRPS type II. The effect of this α1-AR up-regulation on keratinocyte 
function is uncertain, but it is interesting that an elevated sodium channel expression in the 
keratinocytes of patients with CRPS type I may increase their excitability [62]. Keratinocytes are a 
major source of cutaneous nerve growth factor which, after peripheral nerve injury, can stimulate 
hyperexcitability in regenerating afferent nerve fibres [42]. Thus, in the presence of adrenergic 
agonists such as epinephrine or norepinephrine, liberation of inflammatory mediators or growth 
factors from hyperexcitable keratinocytes might contribute to pain. However, this speculation will 
have to be confirmed in further studies.  
In contrast to patients with CRPS type II, α1-AR expression was not altered on keratinocytes in the 
injured limb of rats after PSL. The basis of this discrepancy is unclear, but might involve differences 
in timing (4-28 days after injury in rats compared with months or years after peripheral nerve injury 
in patients with CRPS type II), variation in the location or extent of injury between the animal model 
and the human condition, or differences in the intensity of the neuroinflammatory response that 
might trigger α1-AR up-regulation. In addition, heightened expression of α1-ARs on dermal nerve 
fibres was detected in CRPS patients many months after peripheral nerve injury, but had resolved in 
the papillary dermis within 28 days of PSL in the rodent model. Whether this represents a species 
difference or a characteristic of CRPS is unknown. 
Vascular sensitivity to vasoconstrictor agents, including α1-AR agonists, increases after nerve injury 
[53; 60]. Nevertheless, in the present study, vascular expression of α1-ARs did not change after PSL, 




transporters or other changes (e.g., in gap-junction proteins, angiotensin II receptor expression or 
intracellular signalling to contractile stimuli) may contribute to denervation supersensitivity [53]. 
Alterations in circulatory dynamics resulting from this nonspecific increase in vascular sensitivity 
could augment inflammation and/or pain [56]. 
Overall, our results indicate that α1-AR expression increases on keratinocytes and nociceptive 
afferents after peripheral nerve injury both in a well-characterized animal model of CRPS type II and 
in the human condition. Only one of three patients in this small series clearly benefited from 
regional sympathetic blockade, and none had been treated with adrenergic blocking agents. 
Nevertheless, in uncontrolled trials, non-specific α-adrenergic antagonists such as phentolamine and 
phenoxybenzamine [15; 21; 33] and specific α1-AR antagonists such as prazosin and terazosin 
decreased the pain of CRPS [1; 48]. The present findings establish a mechanistic basis for this 
therapeutic effect in patients with CRPS type II. In particular, α1-antagonists may block the actions of 
circulating or locally secreted catecholamines on neural α1-ARs, or prevent the adrenergic activation 
of keratinocytes. Thus, further exploration of the therapeutic potential of α1-blockers for CRPS type 
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Supplementary Figure e1: α1-AR expression (red) on the smooth muscle cells (green) of a large 
artery in cross-section and a small blood vessel cut longitudinally (upper left). Scale bar = 50 μm. 
Figure 1: Quantification of α1-AR staining intensity in normalised units (Z scores) on nerve fibres in 
the papillary dermis and in large dermal nerve bundles at 4 (A,C) and 28 days (B,D) after PSL. α1-AR 
staining intensity was quantified in 4 different neuronal populations: all neurons labelled with the 
pan-neuronal marker TUJ1; peptidergic neurons labelled with CGRP; non-peptidergic neurons 
labelled with IB4; and myelinated neurons labelled with NF200. * indicates significant differences 
between ipsilateral (filled circles) and contralateral skin (open circles) and # indicates significant 
differences between PSL and sham animals (p<0.05). The horizontal bar in each column represents 
the median. 
Figure 2: α1-AR expression (red) was up-regulated in dermal nerve bundles in skin ipsilateral to PSL 
(A) in comparison to skin contralateral to PSL (D) and that from animals that underwent sham 
surgery (G). Representative images at 4 days after PSL or sham surgery are shown. Nerve fibres were 
identified using the pan-neuronal marker TUJ1 (blue; B, E, H). Co-localized images highlight all pixels 
expressing TUJ1 and a high concentration of α1-AR in white. Scale bar = 50 µm 
Figure 3: Strong α1-AR (red) up-regulation was observed in NF200 labelled fibres (green) in nerve 
bundles after PSL (A-C) in comparison to those in skin contralateral to PSL (D-F) and after sham 
surgery (G-I). Representative images at 4 days after PSL or sham surgery are shown. Co-localized 
images (C, F, I) highlight all pixels that expressed NF200 and a high concentration of α1-AR in white. 
Scale bar = 50 µm  
Figure 4: Nerve bundle from a skin section at 4 days after PSL stained with triple 
immunohistochemistry for α1-AR (red), myelin basic protein (MBP; green) and NF200 (blue). Specific 




analysis was then performed identifying pixels containing co-localized MBP and α1-AR (C) and NF200 
and α1-AR (D). All pixels containing co-localized markers are shown in white in both C and D. Note 
the minimal co-localisation of α1-AR with MBP in B and C. Scale bar = 20 µm. 
Figure 5: α1-AR expression was up-regulated in IB4 axons in the sciatic nerve at 4 days after PSL (A-D) 
in comparison to sciatic nerve after sham surgery (E-H). Arrows show axons that are co-labelled with 
α1-AR, IB4 and TUJ1, which also have up-regulated expression of α1-AR. Scale bar = 50 µm 
Figure 6: Quantification of α1-AR staining intensity in normalised units (Z scores) on (A) dermal nerve 
fibres and (B) in the epidermis of patients with CRPS type II and controls. # α1-AR expression was 
greater in the CRPS-affected limb than in controls (p<0.05). The horizontal bar in each column 
represents the median. 
Figure 7: α1-AR expression (red) was up-regulated on dermal nerve fibres (labelled green) in CRPS-
affected skin in comparison to nerve fibres from the same patient in unaffected skin and in a 
representative pain-free control. Nerve fibres were identified using the pan-neuronal marker 
PGP9.5. Co-localized images highlight all pixels that expressed PGP9.5 and a high concentration of 
α1-AR in white. α1-AR was also expressed in the perineurium surrounding the nerve fibres (red in the 
co-localized images). Scale bar = 20 µm in the columns illustrating α1-AR and PGP-9.5 staining of 
dermal nerve fibres, and 50 µm in images illustrating α1-AR (red) and PGP-9.5 staining (green) more 
broadly in the epidermis and dermis. The boxed areas in images in the far-right column show the 
location of nerve fibres illustrated at higher magnification in the accompanying images.  
Figure 8: α1-AR expression (red) was up-regulated in the epidermis in CRPS-affected skin in 












Table 1. Primary and secondary antibodies used in rat tissues: dilutions and source 




Product code and source 
isolectin B4, FITC conjugate 1:250 1:250 L2895, Sigma-Aldrich 
Primary antibodies 
anti α1-AR, rabbit polyclonal 1:200 1:250 A270, Sigma-Aldrich 
anti neuronal class III β-tubulin 
(TUJ1), mouse monoclonal 
1:800 1:2000 MMS-435P, Covance 
anti CGRP, goat polyclonal 1:400 1:2000 1720-9007, AbD Serotec 
anti NF200, chicken polyclonal 1:4000 1:7500 Jackson ImmunoResearch 
anti MBP, mouse monoclonal  1:400 n/a Sc-66064, Santa Cruz 
anti SMA, mouse monoclonal 1:4000 n/a A2547, Sigma-Aldrich 
Secondary antibodies 
Donkey anti-chicken Cy2 1:600 1:600 Jackson ImmunoResearch 
Donkey anti-goat DyLight-488 1:600 1:600 Jackson ImmunoResearch 
Donkey anti-rabbit Dylight-549 1:1200 1:1200 Jackson ImmunoResearch 
Donkey anti-mouse Dylight-647 1:1000 1:1000 Jackson ImmunoResearch 
 
Abbreviations: α1-adrenoceptor (α1-AR), Calcitonin Gene Related Peptide (CGRP), Myelin Basic 
Protein (MBP), Smooth Muscle Actin (SMA), Neurofilament 200 (NF200), Fluorescein Isothiocyanate 





Table 2. Clinical characteristics of patients with CRPS type II 
Age, 
sex 
Duration Injury Symptoms noted during the 
physical examination 
Effect of regional 
sympathetic 
blockade 
56, F 10 years sciatic nerve crush  Allodynia, very swollen, very 
cold, cyanotic, decreased range 
of motion 
Pain decreased 
48, M 23 
months 
ulnar nerve laceration  Allodynia, mildly swollen, cold, 
decreased range of motion, mild 
dystonia, tremor 
Not tried 
45, F 46 
months 
carpal tunnel surgery  Allodynia, mildly swollen, warm, 
increased sweating, decreased 
range of motion, severe dystonia, 
tremor 
Severe nausea 
44, M 6 months fibula fracture, sural 
nerve surgery  
Allodynia, mildly swollen, 
cyanotic, decreased range of 
motion 
Not tried 
23, M 6 months ulnar nerve laceration  Allodynia, mildly swollen, 
cyanotic, warm, decreased range 
of motion 







After peripheral nerve injury, nociceptive afferents acquire an abnormal excitability to adrenergic 
agents, possibly due to an enhanced expression of α1-adrenoceptors (α1-AR) on these nerve fibres. 
To investigate this in the present study, changes in α1-AR expression on nerve fibres in the skin and 
sciatic nerve trunk were assessed using immunohistochemistry in an animal model of neuropathic 
pain involving partial ligation of the sciatic nerve. In addition, α1-AR expression on nerve fibres was 
examined in painful and unaffected skin of patients who developed complex regional pain syndrome 
after a peripheral nerve injury (CRPS type II). Four days after partial ligation of the sciatic nerve, α1-
AR expression was greater on dermal nerve fibres that survived the injury than on dermal nerve 
fibres after sham surgery. This heightened α1-AR expression was observed on non-peptidergic 
nociceptive afferents in the injured sciatic nerve, dermal nerve bundles and the papillary dermis. 
Heightened expression of α1-AR in dermal nerve bundles after peripheral nerve injury also co-
localised with neurofilament 200, a marker of myelinated nerve fibres. In each patient examined, α1-
AR expression was greater on nerve fibres in skin affected by CRPS than in unaffected skin from the 
same patient or from pain-free controls. Together, these findings provide compelling evidence of an 
up-regulation of α1-ARs on cutaneous nociceptive afferents after peripheral nerve injury. Activation 
of these receptors by circulating or locally secreted catecholamines might contribute to chronic pain 
in CRPS type II. 
 
